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Abstract: Mycobacteria are a large family of over 100 species, most of which do not cause diseases in
humans. The majority of the mycobacterial species are referred to as nontuberculous mycobacteria
(NTM), meaning they are not the causative agent of tuberculous (TB) or leprosy, i.e., Mycobacterium
tuberculous complex and Mycobacterium leprae, respectively. The latter group is undoubtedly the most
infamous, with TB infecting an estimated 10 million people and causing over 1.2 million deaths in
2017 alone TB and leprosy also differ from NTM in that they are only transmitted from person to
person and have no environmental reservoir, whereas NTM infections are commonly acquired from
the environment. It took until the 1950′s for NTM to be recognised as a potential lung pathogen
in people with underlying pulmonary disease and another three decades for NTM to be widely
regarded by the medical community when Mycobacterium avium complex was identified as the most
common group of opportunistic pathogens in AIDS patients. This review focuses on an emerging
NTM called Mycobacterium abscessus (M. abs). M. abs is a rapidly growing NTM that is responsible for
opportunistic pulmonary infections in patients with structural lung disorders such as cystic fibrosis
and bronchiectasis, as well as a wide range of skin and soft tissue infections in humans. In this review,
we discuss how we came to understand the pathogen, how it is currently treated and examine drug
resistance mechanisms and novel treatments currently in development. We highlight the urgent
need for new and effective treatments for M. abs infection as well as improved in vivo methods of
efficacy testing.
Keywords: Mycobacterium abscessus; non-tuberculous mycobacteria; antimicrobial drug discovery;
cystic fibrosis
1. Introduction
Mycobacterium abs was first isolated in 1952 by Moore and Frerichs from a 63-year-old woman’s
knee abscess [1] and since then, our understanding of the pathogen has rapidly and somewhat
turbulently expanded. When it was first isolated, it was suggested by the authors that M. abs was an
entirely new species of nontuberculous mycobacteria (NTM) and was given its name due to its ability
to produce subcutaneous abscesses. Interestingly, at this point, M. abs was considered to be a pathogen
of low virulence due to the perception that it was primarily a pathogen causing cutaneous infections
that appeared transient and self-limiting [1]. 40 years after its discovery, M. abs was first implicated
in pulmonary infections after an analysis of 154 patients with rapidly growing mycobacteria (RGM)
pulmonary infections revealed that 82% of the isolates were M. abs; the disease was considered to be
slowly progressive but virulent nonetheless [2]. This was preceded by an observation of four patients
with pulmonary disease caused by the related organism Mycobacterium chelonae; however, the cause of
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these infections cannot be confirmed as M. abs [3]. Since its first identification, M. abs nomenclature
and species/subspecies identification have undergone many changes.
In 1952 [1], M. abs was believed to be identical to M. chelonae, another RGM that infects fish and
amphibians, as it presented identical biochemical features [4]. Then, in 1972, following an international
collaborative study by the International Working Group on Mycobacterial Taxonomy, M. abs was
designated subspecies status [4]. 20 years later, in 1992, Kusunoki and Ezaki used DNA hybridisation
to establish that there is only 35% DNA relatedness between M. chelonae subsp. chelonae and M. chelonae
subsp. abscessus. In light of this, M. abs was finally re-elevated to species status [5].
However, in 2004, an unusual mycobacterium was isolated from a patient with hemoptoic
pneumonia, and researchers were unable to accurately identify the species using the techniques
described above. They developed partial polymerase chain reaction (PCR) sequencing of the rpoB
gene and were able to demonstrate that the isolate shared 96.0% partial rpoB sequence similarity and a
98.0% recA gene sequence similarly with only the M. abs type strain. They had previously proposed
that rpoB gene sequence difference of >3% and a recA gene sequence difference of >2% was sufficient
to differentiate between different NTM species. Using this new rpoB gene sequencing technique aided
with the more traditional biochemical assays and 16S rRNA gene sequencing, the authors were able to
produce an accurate phylogenetic tree of various NTM. They concluded that this novel isolate was a
new species closely related to and likely recently derived from M. abs. This was subsequently named
Mycobacterium massiliense [6].
In 2006, rpoB gene sequencing was used on 59 clinical isolates of RGM [7], and they found that
15.3% of these isolates were novel, corresponding to three new species of mycobacteria. One of these
species, named Mycobacterium bolletii by the authors, was found to share 100% 16S gene similarity and
95.6% rpoB gene sequence similarity with M. abs.
Over the years, many different biochemical and molecular techniques have been employed to
identify NTM species. Up until the early 2000s, the sodium chloride tolerance test was used to identify
species of RGM, particularly in distinguishing between M. abs and M. chelonae species, as M. abs
is able to grow on Löwenstein-Jensen medium with 5% sodium chloride, but M. chelonae is not [8].
However, several investigators reported that this method is unreliable, likely due to vague criteria
and the cross-over of biochemical features between differing species of RGM [8–10]. The citrate
utilization assay perhaps provides more reliability, the premise being that M. abs is unable to use
citrate as a carbon source whereas other RGM such as M. chelonae are [11]. As is also the case with
the sodium chloride test, this assay takes up to 8 weeks to complete and therefore is losing traction
in the clinical setting [11]. High Performance Liquid Chromatography (HPLC) has also been used to
generate mycolic acid patterns and thus distinguish between RGM species; however, this technique
has limitations as several RGM have similar mycolic acid profiles [12]. Despite its widespread use in
species identification, 16S rRNA sequencing has been shown to be inadequate for species identification
of mycobacteria [6]. An assay with superior specificity was needed to differentiate between NTM
species and subspecies.
In 2011 it was proposed by Leao et al. [13] that the M. abscessus complex (MABS complex)
should be amended to include M. abscessus subsp. abscessus (as before) and to combine the two
subspecies to form one single subspecies, M. abscessus subsp. bolletii. Finally, in 2013, whole-genome
sequencing (WGS) was used by Bryant et al. to identify transmission between patients with cystic
fibrosis (CF) [14]. The authors subjected 168 clinical isolates of M. abs to WGS and a phylogenetic
tree produced from the isolates showed clearly, for the first time, that M. abscessus subsp. abscessus,
M. abscessus subsp. bolletii, and M. abscessus subsp. massiliense are three distinct subspecies belonging
to the MABS complex. The idea that MABS is a complex that contains three subspecies that are
genetically very similar, but phenotypically divergent was given more traction in 2016 when Tortoli
et al., [15] published an amended description of the MABS complex that highlighted the importance
of subspecies differentiation. The authors argued that the criteria for subspecies as proposed by
Wayne et al., [16] i.e., “genetically close organisms that diverge in phenotype” is appropriate in this
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case, considering the genetic similarity and the presence of an inducible and functional erm(41) gene
conferring macrolide resistance in only M. abscessus subsp. bolletii and M. abscessus subsp. abscessus
isolates whereas M. abscessus subsp. massiliense has a non-functional erm(41) gene. Trovato et al.
identified that WGS was effective at discriminating M. abscessus subsp. abscessus from other isolates
with more accuracy than rpoB gene sequencing [17]. An important recent study using WGS on 32 M.
abs isolates, identified multiple subpopulations within each patient, demonstrating that isolates from
sputum do not represent the entire M. abs diversity within a patient. This has serious implications for
isolate sensitivity testing and subsequent infection management [18]. The timeline of M. abs taxonomy
is summarised in Figure 1. It is clear that WGS of clinical isolates is of vital importance for effective
diagnosis and targeted treatment for M. abs infection.
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exposure is extremely common, whereas NTM disease is still relatively rare. Those with pre‐existing 
lung diseases undoubtedly have some predisposition to NTM infection, leading some to describe a 
“two‐hit” theory of NTM disease acquisition [27]. Undoubtedly, the leading population affected by 
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first 50 years since its discovery, no congruent termi ology was in widespread use to accurately describe
and differentiate M. abs from other nontuberculous yc bacteria (NTM). In the mid-2000s, improved
molecular technology resulted in the discovery of the tw M. abscessus subspecies; M. abscessus subsp.
assiliense and M. bsc ssus subsp. bolletii in 2004 and 2006, respectively. Then, in 2011, it was proposed
that M. absces us sub p. massiliense and M. ab cessu su sp. bolletii should be merged into one subspecies,
M. abscessus subsp. massiliense. This cau ed some confu ion within th medical community, until in
2013, when whole genome equencing (WGS) howed genetic division that clearly identified t e three
subspecies within the M. abs complex.
2. M. abscessus and Cystic Fibrosis
NTM species are ubiquitous in the environment (unlike M. tuberculosis and M. leprae, which require
a living host and are transmitted patient to patient or zoonotically), suggesting that NTM exposure is
extremely common, whereas NTM disease is still relatively rare. Those with pre-existing lung diseases
undoubtedly have some predisposition to NTM infection, leading some to describe a “two-hit” theory
of NTM disease acquisition [19]. Undoubtedly, the leading population affected by M. abs is the CF
population. However, there have also been incidences of M. abs infections in non-CF populations.
CF is an autosomal recessive disorder caused by mutations in the CF transmembrane conductance
regulator gene (CFTR). Despite being a multi-organ disease, one of the most prominent features
in CF is chronic pulmonary infection. The major pathogen associated with lung infection in CF
is Pseudomonas aeruginosa, and unfortunately, 80 to 90% of patients with CF die from respiratory
failure as a result of chronic bacterial infection [20]. Even from infancy, the lungs of CF patients are
already commonly colonised with a variety of organisms such as Staphylococcus aureus and Haemophilus
influenzae. Before 1990, NTM infection was not often associated with CF. However, since then, reports of
M. abs infection (along with other NTM species) have been increasingly common. Several large-scale
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studies have been performed over the past decade or so, revealing an NTM prevalence in CF patients
in some areas as high as 20% (Table 1).
Table 1. Prevalence of non-tuberculous mycobacterial lung disease in cystic fibrosis patients in differing
geographical areas between 2004 and 2014. CF: cystic fibrosis.
Study Location Sample Size NTM Prevalence in CF
Oliver, KN (2004) [21] USA 750 13% (majority M. avium complex)
Roux, AL, et al. (2009) [22] France 1582 6.6% (M. abs most common)
Seddon, P, et al. (2013) [23] UK 3805 adults3317 children
5% adults
3.3% children
Adjemian, J, et al. (2014) [24] USA 18,003 10–20%; depending on area
Mussaffi, H, et al. (2005) [25] Israel 139 8.6%
Age is a strong correlator of NTM infection in this group, with 40% of CF patients over the age
of 40 having NTM smear positive results, as opposed to 4–20% in the under-40s population [26].
Other risk factors for NTM infection in CF patients appears to be lower body mass index (BMI)
values, worse forced expiratory volume (FEV1), current infection with Pseudomonas aeruginosa and
Stenotrophomonas maltophilia, experience of pneumothorax requiring chest drain, the use of inhaled
antibiotics and other medical interventions. [27]. Recently, a longitudinal study identified that NTM
infection is increasing in prevalence in the UK pediatric CF population from 1.3% to 3.8% between
2010 and 2015 with a sample size of 5333 patients under 16 years of age [28]. One study performed in
Israel found a significant association between Aspergillus species and NTM species in sputum cultures
of CF patients [29].
M. abs also causes serious disseminated infections following transplantation [30]. A single case
study involving post-transplant M. abs skin and soft tissue infection (SSTI) resulted in disseminated
pulmonary infection and eventually the death of the patient, despite aggressive pre- and peri-operative
anti-mycobacterial therapy [31]. For this reason, many have recommended that M. abs colonisation
should be viewed as a contraindication to lung transplantation. This suggestion, however, has been
met with criticism. Some studies have shown that it is possible to perform a lung transplant on patients
with M. abs colonisation and that subsequent clearance of infection is possible, albeit with a strong
possibility of severe complications [32,33]. Despite this uncertainty surrounding the outcome of lung
transplantation in patients colonised with M. abs, it is increasingly clear that effective treatments for
M. abs lung infection must be developed, as lung transplantation is a potentially life-saving therapy
for end-stage lung disease caused by CF and other lung disorders.
3. M. abscessus Infection in Non-CF Populations
M. abs infection can also occur in non-CF populations. It is well documented that a risk factor
for NTM pulmonary disease is patients with low body fat. The mechanisms behind this are not well
understood; however, it is possible that leptin plays a role in NTM predisposition [34].
Aside from pulmonary infections, M. abs is also able to produce SSTIs in otherwise healthy hosts.
There have been cases of M. abs outbreaks following the use of contaminated needles and other surgical
instruments [35] and even, as was the case in a cohort of ‘lipotourists’ (i.e., people who travel abroad
for cosmetic surgery for fat removal), severe outbreaks following cosmetic surgery [36]. Interestingly,
M. abs has also been linked to late-onset wound infections following crush trauma sustained by
Swedish survivors of the 2004 tsunami that killed over 200,000 people and caused serious crush
injuries in another >2000 [37]. M. abs pulmonary infections in non-CF patients have been previously
reviewed [38].
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4. Environmental Reservoirs and Transmission
NTM are ubiquitous in the environment; especially water sources and soil [1]. They are prone to
biofilm formation and this contributes to their ability to persist in harsh environments [39]. NTM can
persist in environments that are in close proximity to human populations, particularly human water
sources, hospital water supplies (sinks, showerheads) and homes.
M. abs, like other NTM, is able to survive in harsh, nutrient-starved environments where other
competing microorganisms would not survive, such as in chlorinated water [40]. The presence of the
lipid-rich cell wall results in a hydrophobic cell surface, which facilitates the formation of biofilms,
their slow growth and adherence to surfaces, thus aiding their survival and providing them with
a selective advantage [41–43]. Furthermore, many RGM are oligotrophic, requiring low levels of
two carbon sources and minimal amounts of metal ions [44], further indicating their hardiness and
persistence in harsh environments. The impenetrable nature of the M. abs cell wall in comparison
to other non-mycobacterial pathogens also contributes to its resistance to many antibiotics and
disinfectants [45,46]. The ability of M. abs to survive in the human environment presents a huge
problem for human health, with most studies up until this point suggesting that patients with CF
predominately acquire NTM infection from the environment [14]. This long-held belief was called into
question in 2013 when Floto and his team used WGS to show possible patient to patient transmission
of M. abs within a CF clinic in the UK [47].
In 2009, Feazel et al. demonstrated that showerheads provide an enriched environment for
NTM biofilm formation; the presence of human pathogens including NTM were >100 fold higher in
showerhead biofilms compared to the background water contents [48]. A study in Hawaii investigated
the prevalence of NTM in household plumbing; areas such as showerheads, sinks, taps, shower drains
and refrigerator water dispensers were sampled. The authors found that 69% of households surveyed
had clinically significant NTM colonisation, of which 10% was M. abs [49]. Another 2018 study revealed
an outbreak of M. abs skin infections in children who were exposed to the same indoor wading pool [50].
This study demonstrates the importance of identifying M. abs environmental reservoirs, reporting
M. abs cases and subsequent environmental remediation in order to reduce the risk of infection.
The persistence and spread of NTM species within healthcare environments is fast becoming
a serious problem and a significant threat to human health [51]. It was a long-held belief in the
scientific community that NTM is transmitted to humans from the environment, and that patient to
patient transmission is unlikely. This resulted in a clinical focus on reducing the risk of environmental
transmission using effective sterilising techniques and other hygiene practices. Such as it is, the CF
Trust published M. abs infection control recommendations that include general infection control
measures such as hand washing and more specific recommendations such as segregation of infected
patients from other patients [52].
The mode of transmission of pathogenic NTM to humans is still poorly understood, with many
studies seeking evidence of human to human transmission using molecular techniques such as WGS.
A study undertaken in 2001 sought to address this question; a retrospective analysis of 1062 respiratory
specimens taken from 214 patients with CF revealed five patients with M. abs lung infection. These five
patients each had isolates with a unique genotype that was not shared with any of the other patients,
which led the authors to conclude that patient to patient transmission of M. abs was not occurring
within their cohort [53].
In 2014, a small-scale study was performed on 27 M. abs isolates from 20 paediatric CF patients [54].
The authors used a combination of epidemiology, variable number tandem repeat (VNTR) profiling
and WGS to find evidence of cross-infection between paediatric CF patients. It was hypothesized that
patients with strains that had identical VNTR profiles would have had intense exposure to each other
compared with patients with strains that had different VNTR profiles. Little evidence of transmission
between patients was found, except for two patients who were siblings and therefore had higher
intensity of exposure. The authors concluded that cross-infection was uncommon in their cohort,
and that transmission is most likely to be from a common environmental source [54].
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The biggest shift in our understanding of transmission came in 2013 when a major study was
published in which WGS was used to identify transmission of M. abs between patients at an adult
CF centre in the UK between 2007 and 2011 [14]. The authors found a high level of relatedness
between isolates of M. abscessus subsp. abscessus, but clusters were clearly segregated from one another,
indicating that patients have independently acquired either genetically diverse strains or a dominant
circulating clone. However, in the case of M. abscessus subsp. massiliense the authors found isolates
from different individuals with almost identical genomic sequences, strongly indicating transmission
between patients. Analysis of the environment revealed no NTM species isolated from the water
supply to the clinic, showerheads, dish washers, bronchoscopes or the local River Cam or Papworth
Hospital Pond. Further investigation into possible transmission routes revealed patients with isolates
from the same genetic relatedness clusters were present in the clinic at the same time as each other,
further supporting their hypothesis that M. abscessus subsp. massiliense is likely transmitted from
patient to patient rather than independently from the environment. This finding represents a major
clinical advance which may require patients infected with M. abs to be segregated from M. abs-naïve
patients to prevent onward transmission.
Following on from the localised retrospective study published in 2013 [14], a global WGS initiative
was launched on 1080 isolates from 517 patients from the UK, USA, Republic of Ireland, mainland
Europe and Australia [47]. This study found that the majority of isolates were from densely clustered
genotypes that were not diverse, suggesting a high level of human-human transmission. Phylogenetic
analysis also revealed that there are three dominant circulating clones globally, and these clones
are associated with higher virulence and poor clinical outcomes. Human-human transmission
appears to have facilitated the evolution of M. abs from an environmental pathogen to a transmissible
human pathogen.
5. Diagnosis and Treatment:
As M. abs and other NTM species are ubiquitous in the environment, including drinking water
supplies, the presence of culture-positive respiratory tract sample for NTM does not always indicate
NTM-pulmonary disease (NTM-PD). Therefore, patients must also have characteristic symptoms,
compatible radiology, and two or more positive sputum samples for the same NTM species, as well as
the exclusion of other potential causes of pulmonary disease [55].
For clinical laboratory identification of NTM species, the British Thoracic Society (BTS)
recommends that isolates be obtained from sputum samples, and if this is not possible (for example
in children), bronchoalveolar lavage or transbronchial biopsy samples should be taken when NTM
pulmonary disease is suspected [55]. NTM infection can be validated in the laboratory, with the use of
auramine-phenol staining and microscopy, as well as culture on solid and liquid media.
All clinical isolates of M. abs undergo susceptibility testing for clarithromycin, cefoxitin and
amikacin. They also recommend that other antibiotics such as tigecycline, imipenem, minocycline,
moxifloxacin and clofazimine are tested in this manner [55].
6. Treatment
When M. abs was first isolated in 1952, it was thought the patient was initially infected with the
pathogen at the age of 14 years old. The patient’s condition resolved without intervention and so for
some time, treatment wasn’t considered a priority in M. abs infections [1].
Of course, today it is well known that treatment for M. abs pulmonary infection is essential to give
the patient the best chance of survival. Unfortunately, antimicrobial chemotherapy for M. abs infection
is particularly difficult due to its intrinsic and acquired resistance to most of the commonly used
antibiotic classes. Further complications in the treatment of M. abs infection is the lack of evidence that
in vitro susceptibility of antibiotics corresponds to in vivo efficacy in treating pulmonary disease [26].
Because chemotherapy-based treatment of M. abs infection is often unsuccessful, the American Thoracic
Society advises that certain patients may have the best chance of disease regression with resectional
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surgery, especially if the patient exhibits a poor response to drug therapy, if macrolide-resistance
develops, or if the patient is experiencing disease-related complications such as haemoptysis [26].
Current treatment guidelines from the BTS [55] recommend that treatment for M. abs pulmonary
disease should consist of an initial phase antibiotic regimen that includes intravenous (I.V.) and oral
antibiotics, followed by a continuation phase comprising of oral and inhaled antibiotics (Figure 2).
Further genetic analysis of clinical isolates can provide information on the erm(41) (inducible macrolide
resistance) and/or presence of 23S rRNA point mutation (constitutive macrolide resistance) in clinical
isolates of M. abs, which can then be used to inform patient-specific treatment regimens.
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Figure 2. Flow chart showing treatment regimen for M. abs-pulmonary disease based on laboratory
susceptibility testing results as recommended by the British Thoracic Society. Treatment will differ
based on the whether the isolate displays macrolide sensitivity/inducible macrolide resistance or
constitutive macrolide resistance. The initial phase of treatment involves three intravenous (I.V.)
antibiotics, and for macrolide sensitive/inducible macrolide resistance one of two oral macrolides,
and this phase lasts one month. The continuation phase also depends on laboratory susceptibility
testing results and clinicians will typically administer 1-4 oral antibiotics over a period of at least 12
months. It is also important to note that the American Thoracic Society (ATS) recommends surgical
resection of infected area if the patient is not responding to therapy, if macrolide resistance develops
and/or if the patient develops disease-related complications such as haemoptysis.
Side effects of M. abs treatment are common and can be severe. A retrospective analysis of
65 patients undergoing treatment for M. abs lung disease in South Korea [56] revealed frequent
adverse reactions to cefoxitin; 51% of patients developed leukopenia, 6% of patients developed
thrombocytopenia, and 15% of patients experienced drug-induced hepatotoxicity. As a result, cefoxitin
was discontinued in 60% of patients and side effects resolved. Another common side effect observed
was gastrointestinal problems (nausea, anorexia, or diarrhoea), which affected 22% of patients and
caused four patients (6%) to completely stop antibiotic treatment. A clinical recommendation was made
to consider imipenem as an alternative to cefoxitin; however, prolonged treatment with imipenem can
cause neutropenia.
Another study that analysed treatment outcomes in 65 patients with M. abs in North America
also found a high prevalence of side effects. IV amikacin (65% of patients) and azithromycin (71% of
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patients) were the most commonly used antimicrobials in this cohort. They found 74 different side
effects reported in 62% of patients, most commonly nausea/vomiting (31%) and skin changes (20%).
They attributed many of these side effects to amikacin or tigecycline, and as a result, of those received
amikacin or tigecycline therapy, 51% and 36% of patients, respectively, had to adjust or stop medication
due to severe side effects such as ototoxicity. Similar to the South Korean study, four patients had to
totally stop treatment because of their side effects [57].
Clarithromycin is one of the most commonly-used antibiotics to treat M. abs [26].
However, clarithromycin has been associated with hearing loss, with one study citing a 7% hearing loss
rate in their patients. This side effect did resolve in all but one patient; however, the authors state that
the patient had a pre-existing condition that hindered their ability to attribute this hearing loss solely to
clarithromycin [58]. A case study on an 81-year-old woman, who was being treated with clarithromycin
for infective exacerbation of chronic pulmonary obstructive disease (COPD) showed another example
of clarithromycin-related permanent hearing loss, despite evidence that clarithromycin is relatively
well tolerated [59,60]. The major issue with using clarithromycin to treat M. abs is the presence of a
functional inducible erm(41) gene that confers macrolide resistance in both M. abscessus subsp. abscessus
and M. abscessus subsp. bolletii but not M. abscessus subsp. massiliense.
The Resistance Problem: Why the Drugs Don’t Work
M. abs is known for its intrinsic resistance to most chemotherapeutic agents, including all the
anti-tuberculous drugs used to treat M. tuberculosis infection [35,61]. Furthermore, in vitro drug
susceptibility testing on M. abs often proves unhelpful in guiding treatment regimens [62]. There are
a number of natural resistance mechanisms displayed by M. abs (along with other mycobacteria),
including a waxy and impermeable cell wall, drug export systems, antibiotic modifying/inactivating
enzymes and genetic polymorphism of target genes [45].
The greatest contributing factor to the lack of M. abs sensitivity to many major classes of antibiotic
is the mycobacterial cell wall, the role of which has long been studied. The high lipid content and
unusual thickness of the mycobacterial cell wall provides an effective barrier for hydrophilic and
lipophilic agents [63]. In 1990 it was shown that the lack of permeability of the M. chelonae (then grouped
together with M. abs) cell wall plays a vital role in making the pathogen resistant to antibiotics [46].
The cell wall barrier is also responsible for M. abs’ intrinsic resistance to acids and alkalis [64]. The cell
wall of mycobacteria also contains porins; it was shown in 1990 that M. chelonae possesses a 59 kDa
cell wall protein that allows for the diffusion of small, hydrophilic solutes. However, this porin
is minor, unlike that of E. coli where they are the most abundant cell wall protein, explaining the
low permeability to hydrophilic solutes [65]. The cell wall cannot explain all of the intrinsic drug
resistance seen in M. abs; in fact, it is known that the cell wall, particularly the porins, act synergistically
with internal systems that are activated by the presence of intracellular antibiotics, and that the low
permeability of the mycobacterial cell wall means that the bacteria has time to induce the expression of
drug resistance genes [65].
As a constituent of the mycobacterial cell wall, active efflux pumps can be described as one
of the main causative factors of drug resistance in mycobacteria [45,66,67]. They primarily act
to protect bacteria against toxic compounds and promote bacterial homeostasis by transporting
toxins or metabolites to the extracellular environment [67]. M. abs encodes protein members
of the major facilitator family ATP-binding cassette (ABC) transporters as well as mycobacterial
membrane protein large (MmpL) families [68]. ABC transporters are found in all forms of
life and make use of adenosine triphosphate (ATP) to transport molecules across membranes.
The MmpL transporter family is a subclass of a large family of multidrug resistance pumps known
as Resistance-Nodulation-Cell-Division (RNCD) permeases. MmpLs export lipid components across
the cell envelope of mycobacteria [69]. The role of MmpLs in M. abs drug resistance is yet to be
fully understood; however, there is evidence that MmpL7 in M. tuberculosis confers resistance to
isoniazid [70], suggesting that MmpLs may play a major role.
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Macrolides are one of the mainstays of M. abs treatment [26], yet despite this, M. abs infections tend
to respond poorly to macrolide therapy, even when they appear sensitive to clarithromycin in vitro [71].
A study performed in 2009 revealed the presence of an inducible erm(41) gene in 7 out of 10 M. abs
clinical isolates that confers resistance to macrolides with a minimum inhibitory concentration (MIC)
of ≥32 µg/mL. The three remaining susceptible isolates had erm(41) gene; however, it appeared to
be non-functional [71]. The erm(41) gene produces a functional 23S rRNA methylase, contributing to
macrolide resistance along with point mutations in the rrl encoding 23S rRNA gene [72]. Following
on from this, it was shown that macrolides may be useful in treating approximately 20% of M. abs
infections in the U.S., and that sequencing of the erm(41) gene is a potentially useful tool in predicting
macrolide susceptibility [73]. It is also noteworthy that M. abscessus subsp. massiliense contains a large
97 base pair deletion in erm(41), rendering it useless. Therefore, M. abscessus subsp. massiliense retains
susceptibility to macrolides, except in the case of rrl mutants [71,74–76]. M. abs isolates possessing an
rrl mutant display constitutive resistance to macrolide antibiotics. This phenomenon is known to be
mediated by a mutation in rrl encoding the bacterial 23S rRNA gene, particularly at positions 2058 and
2059, i.e., the drug binding pocket of the gene [77].
If macrolide therapy is not advised due to evidence of constitutive resistance, there are of course
other chemotherapeutic options available. However, in many of the conserved genes in M. abs that can
potentially act as drug targets, there is the presence of genetic polymorphisms, which can often confer
drug resistance [45].
A 1998 study revealed an amino acid substitution at position 83 (Ser83Ala) in the
quinolone-resistance-determining-region (QRDR) in fluoroquinolone-resistant isolates of M. abs [78].
This substitution occurs in the region of DNA gyrase subunit GyrA that binds DNA, and as
fluoroquinolones bind strongly to the gyrase-DNA complex, and weakly to protein or DNA alone,
this mutation results in fluoroquinolone resistance [79]. Genetic polymorphisms also occur within the
emb operon that codes for several homologous arabinosyl transferases. These are enzymes involved
in the polymerisation of arabinogalactan, an essential component of the mycobacterial cell wall and
can be inhibited by the tuberculosis drug ethambutol. A 1997 study showed that polymorphisms
at position 306 in a highly conserved embB gene conferred natural resistance across many species
of mycobacteria, including M. abs [79]. M. abs has high natural levels of resistance to ethambutol
(MIC >64mg/L), and the same study transferred the M. abs emb region to ethambutol-susceptible
M. smegmatis resulted in a 500-fold increase in the MIC to ethambutol [61].
M. abs also produces a number of target-modifying enzymes. Rifampicin ADP-ribosyl transferase,
Arr_Mab inactivates rifamycins such as rifampicin. Aminoglycoside 2′-N-acetyltransferase and
aminoglycoside phosphotransferases mediate the susceptibility to aminoglycoside antibiotics. M. abs
has also been shown to produce an endogenous β-lactamase (BlaMab), which efficiently hydrolyses the
β-lactam ring of β-lactam antibiotics, rendering them ineffective [61,80,81].
Aside from antibiotic-specific internal drug resistance mechanisms, a family of transcriptional
regulators, the WhiB family, is excusive to actinomycetes and may be involved in conferring drug
resistance in M. abs. Members of this family have been shown to regulate systems of drug resistance
in M. tuberculosis, including antibiotic export and activation [82]. M. abs has been shown to possess
a homologue of the M. tuberculosis WhiB7. When M. abs WhiB7 is deleted, the result is increased
sensitivity to clinically relevant antibiotics that target the ribosome, such as clarithromycin, amikacin
and tetracycline [83].
7. Future Perspectives for M. abscessus
Future Treatments
It perhaps goes without saying that there is an urgent, unmet need for safe and effective treatments
against M. abs pulmonary disease. There have been instances of successful treatment of M. abs with
already available antibiotics. One such case was reported in 2002, where a 63-year-old patient whose
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infection had not responded to the traditional regimen was prescribed a course of faropenem, a new
member of the β-lactam antibiotic class. Treatment was successful and produced no adverse side
effects [84]. It is not just antimicrobials that have potential in enhancing M. abs treatment. In 2012,
Okazaki et al. reported that the use of clarithromycin, amikacin and imipenem/cilastatin to treat a
case of M. abs pulmonary was greatly enhanced with the addition of corticosteroids. The authors
recommend that the presence of organising pneumonia (a non-specific inflammatory pulmonary
process) or an allergic reaction may have helped to explain the poor response to antibiotic treatment
alone in some patients, and that this possibility should be considered when applicable to improve
treatment outcomes [85].
One of the enzymatic resistance mechanisms employed by M. abs is the production of an
endogenous β-lactamase, BlaMab (Figure 3). Cefoxitin and imipenem, both β-lactam antibiotics,
are commonly used to treat M. abs. In order to improve the efficacy of these antibiotics, a β-lactamase
inhibitor may be administered in conjunction during therapeutic treatment. A 2015 study revealed
that avibactam, a β-lactamase inhibitor is able to efficiently inhibit BlaMab [86], and a subsequent 2017
study showed that avibactam improves the efficacy of imipenem against M. abs both in vitro and in
macrophage and zebrafish models of infection [87].
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Figure 3. Graphical summary of the resistance mechanisms exhibited by Mycobacterium abscessus
(M. abs). There are several mechanisms involving different physiological, enzymatic and genomic
processes that contribute to the notoriously drug-resistant profile of M. abs. It is likely that these
processes, such as efflux pumps and drug resistance genes, work in synergy to produce a highly
resistant pathogen.
Aside from these examples, very few case studies have reported successful treatment with
repurposed antibiotics. Therefore, novel drug targets in M. abs must be discovered and elucidated,
and novel compounds that safely and effectively inhibit these targets discovered.
There are potentially a wide variety of viable drug targets in M. abs (Figure 4). Many of the most
promising leads against M. abs have come about as a result of concerted effort to find novel drugs
for M. tuberculosis, which a handful of researchers have applied to M. abs and other NTM species.
Unfortunately, only a small percentage of the novel drugs which are active against M. tuberculosis,
are also active against M. abs, further highlighting just how resistant and dangerous this pathogen is
proving to be.
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processes. Many of the drugs with potential to be used as part of M. abs treatment are old classes of
antibiotics that have been repurposed, such as β-lactamase inhibitors, or have been discovered as part
of the anti-tuberculous drug discovery pipelines, such as bedaquiline.
One potential target in M. abs is DNA gyrase, despite the fact that M. abs is naturally resistant
to quinolones [78], a novel fluoroquinolone, DC-159a was developed in 2010 as part of the Working
Group on TB Drugs, and was found to be active against M. abs with an MIC of 16 µg/mL, which was
four to eight-fold lower than the other already available quinolones tested [88]. The authors stressed
the importance of in vivo testing of DC-159a; however, no publications attesting to the in vivo activity
of DC-159a against M. abs have been released to date.
The mycobacterial cell wall, in all its complexity, can offer an attractive range of potential
antibiotic targets. The three distinct layers of the mycobacterial cell wall: core peptidoglycan,
arabinogalactan and mycolic acids are each essential to the pathogen and involve a number of
exploitable processes [89]. A 2010 study subjected several species of NTM to a capuramycin
analogue SQ641 [90]. Capuramycins are a novel class of nucleoside antibiotics that work by targeting
phosphor-N-acetylmuramyl-pentapeptide-translocase (translocase-1 or TL-1), which is essential for
peptidoglycan synthesis. They found that the drug had an MIC of 0.25-1 µg/mL, as well as finding
synergy between SQ641 and rifabutin and streptomycin. This drug has great potential as it is fast-acting
and displays a long post-antibiotic effect [91]. In 2017 a study was published in which several members
of the newly synthesized MmpL3 inhibitors, indole-2-carboxamides, have shown potent activity
against M. abs. These inhibitors have been shown to work by inhibiting the transfer of mycolic acids
to their cell envelope acceptors in M. abs strains [92]. Further work has been done on this class of
inhibitors; in 2019, Pandya et al. reported that oral administration of the inhibitors shows a statistically
significant reduction in bacterial load in the lungs and spleens of M. abs-infected mice [93].
It has been demonstrated that M. abs displays high levels of intrinsic resistance to the tetracycline
class of antibiotics via the monooxygenase, MabTetX, a WhiB7-independent pathway [94]. This is not
the end of the road for this class of antibiotics. Tigecycline, the first developed glycylcycline, a new
class of tetracycline antibiotics originally developed for SSTIs, was shown in 2014 to be highly effective
in vivo against M. abs pulmonary disease [95]. Further work in 2018 revealed that tigecycline is a
poor substrate of MabTetX and is incapable of inducing its expression, explaining its high efficacy
in comparison with other tetracycline antibiotics [94]. Tigecycline is now one of the recommended
treatment options for M. abs pulmonary disease, and is arguably one of the most effective, with one
study citing clinical improvement in >60% patients with M. abs pulmonary disease when tigecycline is
employed as part of the multi-drug regimen against M. abs [95]. Tigecycline is not the only tetracycline
showing activity against M. abs. A 2012 study tested the in vitro activity of a novel fluorocycline
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antibiotic, TP-271 (a tetracycline-related antibiotic) against 22 isolates of M. abs. They found all the
isolates to have an MIC of ≤1 µg/mL with an average of 0.5 µg/mL, which is decidedly superior to
that of the other orally available tetracycline antibiotics [96].
Bedaquilin, the latest drug indicated for the treatment of multi-drug resistant TB (MDR-TB)
was approved by the FDA in 2011, and it works by targeting the ATP synthase of mycobacteria.
Obregon et al. [97] demonstrated an MICs of 1.0 µg/mL against M. abs reference strain and then in
2017, Vesenbeckh et al. pointed to bedaquiline as a potential antimicrobial against M. abs after the
drug exhibited MICs of ≤1 µg/mL against 20 M. abs clinical isolates in vivo [98]. In vitro activity has
also been observed against a variety of M. abs isolates with both tedizolid and clofazimine; however,
these compounds are yet to be tested for activity in vivo [99,100].
8. Summary
M. abs is increasingly being recognised as an important pathogen responsible for a wide range
of infections and implicated in severe, and often untreatable pulmonary infections in people with
CF and other structural lung disorders. Despite considerable recent progress, there remain many
unanswered questions about this pathogen’s virulence, transmission and environmental persistence.
Furthermore, almost all of the currently available antibiotics are useless against M. abs, with even
official guideline treatment regimens having little to no evidence of in vivo efficacy. With such high
treatment failure rates, clinicians are often forced to administer last-resort antibiotics in the hope of
a cure. Coupled with increasing prevalence and its already extensively drug resistant profile, it is
glaringly obvious that novel, effective and safe treatments are needed. Many of the novel drugs
mentioned above are in various phases of clinical trial against M. tuberculosis and there is a significant
paucity of data regarding their efficacy against M. abs and other NTM species. Furthermore, there is a
startling lack of in vivo efficacy data for any of these drugs, which is particularly worrying considering
the inconsistencies between in vitro and in vivo anti-M. abs activity. Whilst TB has many dedicated
drug-discovery programmes, NTM has none. A dedicated NTM drug discovery pipeline is essential to
ensure the disease burden of NTM does not become overwhelming.
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